Austin resident claims $1 million winning Texas Lottery ticket
AUSTIN (KXAN) — An Austinite claimed a winning Texas Lottery ticket worth $1 million that they purchased at an east Austin 7-Eleven.
According to the Texas Lottery, the top prize-winning ticket was part of the scratch ticket game $1,000,000 Blitz. The person who claimed the winning ticket chose to remain anonymous.
What is the largest lottery prize ever won in Texas?
The ticket was sold at 7-Eleven Convenience Store #38613A, located at 6000 FM 969 Road, Austin.
The Texas Lottery said this was the first of four top prizes worth $1 million to be claimed in this game. $1,000,000 Blitz offers more than $103 million in total prizes. Overall odds of winning any prize in the game are one in 3.74, including break-even prizes, according to the lottery.
Here's what's more — and less — likely to happen than you winning the lottery
A Round Rock resident also claimed a winning ticket worth $1 million less than a month ago. The person took home a $1 million Mega Million prize during the drawing on Dec. 27, missing the $1.2 billion Mega Ball Jackpot prize by one digit, according to a release from the Texas Lottery.
That winning ticket was purchased from a 7-Eleven convenience store in Arlington.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea,' 'Biomea Fusion' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company's investigational, next-generation oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The weight reduction study was conducted in 15 obese cynomolgus monkeys. The study demonstrated a clear, dose-dependent reduction in daily food intake and pronounced and continuous weight loss over a 28-day treatment period. BMF-650 was administered orally once daily at 10 mg/kg and 30 mg/kg and resulted in marked reductions in food intake and progressive body weight reductions, with the respective dose groups achieving a 12% and 15% average weight reduction from baseline over 28 days. These effects compared favorably to published preclinical data of another leading oral GLP-1 RA candidate in development. 'These new findings are especially relevant given the functional similarities between monkey and human GLP-1 receptors. These data disclosed today further support our goal of developing a next-generation oral GLP-1 receptor agonist with enhanced pharmacokinetic properties, specifically a more consistent plasma exposure and improved bioavailability, while preserving the potent metabolic effects observed with injectable therapies,' said Thorsten Kirschberg, Executive Vice President of Chemistry at Biomea and program lead for BMF-650. 'These data reinforce BMF-650's potential as a best-in-class oral GLP-1 RA with robust metabolic effects. We believe the pronounced and consistent appetite suppression and weight loss observed in primates, together with earlier data on glucose-lowering and oral bioavailability, provide strong support for advancing BMF-650 into clinical development.' Study Design and Key Preclinical Findings The study assessed 15 obese cynomolgus monkeys, randomized into three groups receiving vehicle, BMF-650 at 10 mg/kg, or BMF-650 at 30 mg/kg daily for 28 days. Daily food intake was reduced to an average of 35g/day (10 mg/kg) and 16g/day (30 mg/kg) versus 109 g/day for the vehicle control group. BMF-650 induced rapid and durable weight loss during the study, with reductions of 12% (10 mg/kg) and 15% (30 mg/kg) from baseline at Day 28. BMF-650 was generally well tolerated, with no aminotransferase (AT) elevations. BMF-650 Preclinical Highlights Similar to the broader orforglipron chemotype class, designed to improved PK properties, enhance oral bioavailability, achieve less variability and higher plasma protein binding for a potentially enhanced safety and tolerability profile. Goal to achieve a more patient-friendly dose escalation profile than current GLP-1 RAs. Demonstrated robust glycemic control and appetite suppression in multiple preclinical models resulting in pronounced and dose-dependent weight reduction. Generally well tolerated without safety concerns outside of the observed class effects. Next Steps Investigational New Drug (IND) submission on track for the second half of 2025. Phase I trial in obese, otherwise healthy volunteers anticipated to begin in late 2025, subject to IND clearance. A full set of preclinical data for BMF-650 is planned for submission and presentation at an upcoming medical conference. About BMF-650BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, BMF-650 is designed to combine enhanced oral bioavailability and durable receptor activation to deliver robust metabolic benefits. In preclinical studies, BMF-650 demonstrated a favorable PK profile with higher bioavailability and less inter-individual variability compared to published third-party preclinical data on another oral GLP-1 RA. These attributes may support improved tolerability and more effective dose escalation in clinical settings. BMF-650 significantly enhanced glucose-stimulated insulin secretion in both human donor islets and in vivo in non-human primates and showed robust glucose-lowering activity and appetite suppression in cynomolgus monkey models. Notably, daily oral dosing resulted in dose-dependent reductions in food intake and progressive weight loss across the treatment period in a study with obese cynomolgus monkeys. Biomea's development strategy for BMF-650 focuses on achieving steady plasma levels and increased drug exposure (AUC) to support a potential best-in-class profile among oral small-molecule GLP-1 therapies. BMF-650 is currently advancing through IND-enabling studies, with submission of an IND application on track for the second half of 2025. About ObesityObesity is a chronic disease necessitating long-term management, associated with diminished life expectancy and a spectrum of severe health complications. These include metabolic disorders such as type 2 diabetes and metabolic liver disease; cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and hypertension; and increased risks of chronic kidney disease, certain cancers, and chronic inflammation. The Centers for Disease Control and Prevention estimates that over 40% of adults in the United States suffer from obesity, contributing to a significant burden on public health and healthcare systems. Globally, over 650 million adults are living with obesity, and these numbers are steadily rising. About GLP-1 Receptor AgonistsGLP-1 is a naturally occurring incretin hormone that plays a vital role in glucose homeostasis and appetite regulation. GLP-1 RAs are a class of medications that bind to and activate GLP-1 receptors, mimicking the effects of native GLP-1. These agents have demonstrated robust clinical efficacy in improving glycemic control, promoting weight loss, and enhancing insulin sensitivity in individuals with type 2 diabetes and obesity. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X, and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-650, the potential of BMF-650 as a treatment for type 2 diabetes and obesity, our research, development, partnership and regulatory plans, the mechanism of action of our product candidate and development programs; the progress and initiation of our ongoing and upcoming clinical trials, including our planned IND submission for BMF-650 and our anticipated initiation of a Phase I study for BMF-650 following IND clearance, the anticipated availability of data from our clinical trials; our planned interactions with regulators and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that results of preclinical studies may not be predictive of future preclinical results or clinical results in connection with planned clinical trials and the risk that we may encounter delays in preclinical or clinical development, interactions with regulatory authorities related to clinical development, and in the initiation, conduct and completion of our planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
4 hours ago
- Newsweek
Israel's Missile Defenses Running Short as Iran Fires Hypersonics: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Israel is running low on its supply of Arrow missile interceptors just as Iran unleashes hypersonic missiles in its latest attack, according to The Wall Street Journal. Citing a senior U.S. official, the report said American defense leaders have known for months about the shortfall, raising urgent questions about Israel's ability to defend itself from high-speed, long-range threats. The revelation coincides with Iran's announcement that it fired Fattah-1 hypersonic missiles at Israel on Wednesday. The missiles, which travel at more than five times the speed of sound and can maneuver mid-flight, pose a serious challenge to even advanced missile defense systems. Newsweek has reached out to the Israel Defense Forces and Iran's foreign ministry. Why It Matters Israel's Arrow system is a key part of its multi-layered missile defense, built to intercept long-range ballistic threats. A shortage of interceptors during the sixth day of active conflict with Iran could leave major population centers increasingly vulnerable—especially as Iran now deploys faster, more evasive hypersonic missiles. The introduction of such advanced weapons has reshaped the threat landscape. As both nations trade strikes and diplomacy stalls, military readiness—and the ability to intercept incoming fire—has become a defining factor in the escalating confrontation. Iranian missiles face off israeli interceptive missiles over Beirut, Lebanon. June 14 2025. Iranian missiles face off israeli interceptive missiles over Beirut, Lebanon. June 14 2025. Nael Chahine/AP Photo What to Know The shortage of Arrow interceptors stems from intense missile barrages in recent days combined with limited production capacity. A senior U.S. official told the Wall Street Journal that Washington has been aware of the issue for months and has responded by deploying additional American assets across land, sea, and air in the region. However, the official did not specify how many interceptors remain or when production might replenish Israel's stockpile. Defensive Missile System It [Israel] will expand its target sets to increase the pain and force the Iranian regime to change its behavior. Seth Krummrich, Retired U.S. Army Colonel Jointly developed by Israel and the U.S., the Arrow system defends against long-range ballistic threats with layered coverage beyond Patriot and David's Sling. Arrow 2 targets missiles in the upper atmosphere, while Arrow 3 intercepts them in space. Both use high-speed "hit-to-kill" technology and support Israel's broader missile shield, including Iron Dome. Hypersonic Retaliation Yet hypersonic missiles like Iran's Fattah-1 pose a new and serious challenge. Their extreme speed—over five times the speed of sound—combined with mid-flight maneuverability makes them far harder to track and intercept, even for advanced systems like Arrow. Iran said it had fired Fattah-1 hypersonic missiles at Tel Aviv, saying the strikes "shook the shelters" across the city. Iran state media released video footage of the launches, highlighting Tehran's expanding military capabilities. Alongside the hypersonic missiles, Iran also deployed a "swarm of drones" targeting Israeli territory, further complicating the defense landscape. Video released by Iran's IRGC show the moment Iran launched missiles against Israel Follow — Press TV 🔻 (@PressTV) June 18, 2025 Israel retaliated with strikes on weapons factories and a centrifuge plant in Tehran, after warning civilians to evacuate the area. The IDF also intercepted two drones over the Dead Sea. Though casualties were minimal, the use of advanced missiles and drones marks a sharp escalation in the conflict's intensity and sophistication. US Weighs Options Amid the intensifying conflict, President Donald Trump reiterated his support for Israel but signaled growing impatience with Tehran. While the administration has so far avoided direct military engagement, U.S. officials confirmed that the USS Nimitz carrier strike group has been deployed to the region, and Trump convened his National Security Council to discuss possible options. No decision on intervention has been announced, but officials say military involvement remains under consideration. The developments came as Iran claimed to have struck what it described as a Mossad intelligence facility inside Israel, escalating tensions further. Rescue team work at the site where a missile launched from Iran struck Tel Aviv, Israel, Monday, June 16, 2025. Rescue team work at the site where a missile launched from Iran struck Tel Aviv, Israel, Monday, June 16, 2025. Baz Ratner/AP Photo What People Are Saying Seth Krummrich, Retired U.S. Army Colonel and Vice President at Global Guardian told Newsweek: "Initially, Israel focused primarily on military and nuclear targets. If Israel does not achieve the effects it wants, it will expand its target sets to increase the pain and force the Iranian regime to change its behavior. I expect to see expanded targeting of governmental facilities and oil and gas infrastructure to continue to increase the pain level to an intolerable level that Iran has to negotiate. Iran will continue to launch ballistic missile strikes against any Israeli targets with the goal of wearing down Israel's will and reducing Israel's interceptor stockpile to do more damage." What Happens Next As missile technology evolves and tensions rise, Israel's ability to restore interceptor supplies may shape not only the conflict's trajectory but the broader stability of the region. Whether the U.S. remains on the sidelines or steps in more directly could depend on how long Israel can hold the line.
Business Wire
6 hours ago
- Business Wire
Circus SE wins HEM fuel stations as customer for its autonomous AI-robotics in food service
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global leader in AI software and robotics for the food service industry, has secured Deutsche Tamoil and its fuel station brand HEM as a new customer. Together, they are planning for the deployment of the AI-powered cooking robot, the Circus Autonomy One (CA-1). With this move, HEM is setting a forward-looking milestone: in the future, freshly prepared meals will be created fully autonomously through an integrated robotics solution within the service station. This will, for the first time, enable real-world insights into scalability and customer experience. 'We are absolutely delighted to bring the CA-1 robot into the heart of mobility – the dense network of gas and charging stations across Germany,' says Nikolas Bullwinkel, CEO of Circus SE. 'This is a major opportunity to make high-quality meals available everywhere and in the shortest time – precisely where people are on the move.' 'At HEM, we are always looking for innovative solutions to offer our customers genuine added value,' says Carsten Pohl, Managing Director of Deutsche Tamoil GmbH. 'The CA-1 allows us to implement a truly unique and innovative food offering at our stations. We look forward to taking this step into the future together – and are excited for the rollout later this year.' In addition to the CA-1 robot, the full Circus AI-software will be deployed — including a cloud-based point-of-sale system, real-time production control, user-friendly ordering terminals, and data-based performance monitoring — ensuring consistently high-quality meals, anytime and anywhere. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply — on a mission to fuel humanity. About HEM and Tamoil Deutsche Tamoil GmbH, headquartered in Hamburg, is part of the Netherlands-based Oilinvest Group, which operates approximately 2,450 fuel stations and owns a refinery in Hamburg. With over 400 HEM stations in Germany, the company focuses not only on fuel sales but also actively invests in digital services and alternative energy sources to drive forward modern mobility solutions. Thanks to lean structures and efficient cost management, HEM is often able to offer fuel at lower prices than major competitors. For more information, visit or follow HEM on Facebook and Instagram.
